Cidara is a clinical-stage biotechnology company focused on the development of new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Our pipeline includes CD101 IV, a long-acting echinocandin antifungal, and CD201, our lead antimicrobial candidate for multi-drug resistant bacteria generated by our Cloudbreak™ immunotherapy discovery platform.
Recent News and Insights
-
Cidara to Present at Two Upcoming Conferences Sep 18, 2017
-
Cidara to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress Sep 7, 2017
-
T2 Biosystems and Cidara Announce Partnership for Commercial Placement of T2Dx Instruments to Support CD101 Drug Trials Sep 6, 2017
-
View all News Releases
Our Mission
Cidara seeks to save or improve patients’ lives through the development of anti-infectives that transform the standard of care. Our initial portfolio is comprised of proprietary product candidates for the treatment of serious fungal and bacterial infections.
There is an urgent and growing need not only for improved anti-infectives but also for entirely new therapeutic approaches to treat and prevent fungal, bacterial, and viral pathogens, particularly those that are increasingly resistant to available treatments.
CD101 IV
CD101 IV is a novel echinocandin antifungal with potent activity against Candida, Aspergillus and PCP. We are developing CD101 IV for once weekly use in treatment and prophylaxis. We are currently conducting an international Phase 2 trial (STRIVE) in candidemia and invasive candidiasis.
Cloudbreak™ / CD201
Cloudbreak is a proprietary immunotherapy discovery platform that has the potential to do for infectious disease what immunotherapy has done for cancer. CD201 is our lead Cloudbreak candidate intended to direct a patient’s immune cells to attack bacterial infections.